Vnutriplevral'naya immunoterapiya interleykinom-2 bol'nykh s metastaticheskim plevritom

Abstract

The paper gives the results of a study of the clinical efficiency of intrapleural immunotherapy with low-dose recombinant interleukin-2 (roncoleukin®) in patients with metastatic exudative pleurisy in breast cancer, non-small cell lung cancer, ovarian cancer, etc. It has been shown that this treatment modality is highly effective (an objective response was 84%), increases longevity and quality of life in patients, rarely causes recurrences, and it is easy-to-use and well tolerated. Intrapleural immunotherapy for malignant pleural effusion may be successfully used in drug-unresponsive patients and it is one of the stages of multimodality therapy for a disseminated tumor process.